Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity.
about
Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agentsThe clinical potential of influencing Nrf2 signaling in degenerative and immunological disordersThe Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Comprehensive analysis of loops at protein-protein interfaces for macrocycle design.Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Non-electrophilic modulators of the canonical Keap1/Nrf2 pathwayDirect Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display.PinaColada: peptide-inhibitor ant colony ad-hoc design algorithm.Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction InhibitorsIdentification of novel Nrf2 activators from Cinnamomum chartophyllum H.W. Li and their potential application of preventing oxidative insults in human lung epithelial cellsDevelopment of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases.Peptide Macrocycles Developed from Precisely Regulated Multiple Cyclization of Unprotected Peptides.Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a reviewThe mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding
P2860
Q28085561-3A9D67D6-C550-43C3-8C37-58AE99DA10D6Q28395641-2C84E8A1-6D71-4BD3-A4B7-FA73D7387F78Q33659621-46B82266-512A-4EC7-84BF-AD122178E4F1Q35209185-8558E6C8-EA3A-4785-A461-B8A4A127AF35Q35981250-BB02FDBA-77F4-44EC-94AF-3CCE1C12C976Q36277241-02B726FF-E614-4ED4-BB72-0A953DB836A7Q36295178-6A077AF3-6E2F-4016-AC0D-A986AB0B71FDQ36368828-CE0D84A6-A304-4697-9CC1-91B1F4F4CBE3Q39788518-AFE4F1AE-2A20-4652-B8C0-BFDEA3733458Q41064004-C5CCCA24-5CC3-406B-9A5D-6363B2217E4AQ41858529-B0B4F496-2F31-4E2C-A53C-F33C87365223Q41897701-B46D4F7D-87B5-4AAB-BC71-CF374AF97BF5Q41980350-49C51941-9B61-41A2-864C-2298936EF548Q47763404-EACF7929-2192-4802-991A-DA0CF2A2A97BQ57069735-8562F0F5-8B21-4625-9570-4E1E31EFDE09Q58701352-2CD620A1-8D6D-4E58-89A7-DC7FF888A6AC
P2860
Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Peptide inhibitors of the Keap ...... binding and cellular activity.
@en
Peptide inhibitors of the Keap ...... binding and cellular activity.
@nl
type
label
Peptide inhibitors of the Keap ...... binding and cellular activity.
@en
Peptide inhibitors of the Keap ...... binding and cellular activity.
@nl
prefLabel
Peptide inhibitors of the Keap ...... binding and cellular activity.
@en
Peptide inhibitors of the Keap ...... binding and cellular activity.
@nl
P2093
P2860
P356
P1476
Peptide inhibitors of the Keap ...... binding and cellular activity.
@en
P2093
Helene Pfister
Marjolein Schaap
Rowena Hancock
P2860
P304
P356
10.1039/C3OB40249E
P577
2013-04-24T00:00:00Z